

## DAFTAR PUSTAKA

- Ageno, W., Gallus, A.S., Wittkowsky, A., Crowther, M., Hylek, E.M., and Palareti, G., 2012. Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9<sup>th</sup> ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. **CHEST: Official Publication of the American College of Chest Physicians**, p. 50-58.
- Al-Hajje, A.H., Atoui, F., Awada, S., Rachidi, S., Zein, S., and Salameh P., 2012. Drug-Related Problems Identified by Clinical Pharmacist's Students and Pharmacist's Interventions. **Annales Pharmaceutiques Francaises**, p. 1.
- American Society of Health-System Pharmacists. 2011. **AHFS Drug Information Essentials**. American Society of Health-System Pharmacists, USA.
- Arboix, A. and Alio, J., 2010. Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis. **Current Cardiology Review** Vol. 6 No. 3, p. 150-161
- Armaganijan, L., Patel, D., Dietrich, C., and Morillo, C.A., 2012. Stroke Prevention in Atrial Fibrillation: Latest Clinical Trials and Guidelines. **Pharmaceuticals**, p. 386-387.
- Baglin, T., Keeling, D., and Kitchen, S., 2012. Effects on Routine Coagulation Screens and Assesment of Anticoagulant Intensity in Patients Taking Oral Dabigatran or Rivaroxaban: Guidance from The British Committee for Standards in Haematology. **British Journal of Haematology Guideline** 159, p. 427-429
- Baoezier, F., Anggraeni, R., Sjahrir, M.I., Susilo, H., dan Islam, M.S., 2006. Gangguan Pembuluh Darah Otak. Dalam **Pedoman Diagnosis dan Terapi Bag/SMF Ilmu Penyakit Saraf** Ed. III. Surabaya: RSUD Soetomo Surabaya, p. 26-29.
- Bauer, K.A., 2013. Pros and Cons of New Oral Anticoagulants. **Hematology**, p. 465-467.

- Beri, P. and Punnam, S.J., 2008. Anticoagulation in Patients with Acute Ischemic Stroke and Atrial Fibrillation-a Balance of Risks and Benefits. *Cardiovascular Drugs Therapy* 22, p. 420.
- Brighton, T., 2010. New Oral Anticoagulant Drugs-Mechanism of Action. *Experimental and Clinical Pharmacology*.
- Cairns, J.A., Connolly, S., McMurry, S., Stephenson, M., and Talajic, M., 2011. Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter. *Canadian Journal of Cardiology*, p. 80.
- Cervera, A. and Chamorro, A., 2010. Antithrombotic Therapy in Cardiac Embolism. *Current Cardiology Reviews* 6, p. 227-237.
- Clarke, R., Ross, S., Walker, T., and Woods, D., 2006. *INR Testing*. BPACnz Better Medicine, p. 5.
- Cushman, M., Lim, W., and Zakai, N.A., 2011. **Quick Reference 2011 Clinical Practice Guide on Anticoagulant Dosing and Management of Anticoagulant-Associated Bleeding Complications in Adults**. American Society of Hematology, p. 2.
- Davey, L., 2013. Guidance for Prescribing of Dabigatran (Pradaxa) Rivaroxaban and Apixaban in Patients with Non-Valvular AF. *Strategic Clinic Network Lanchashire*
- Deryke, X.L. and Baldwin, K.A., 2012. Management of Acute Ischemic Stroke and Transient Ischemic Attack. PSAP-VII. Book 10, **Neurology and Psychiatry**, p.73.
- Diener, H.C., Easton, J.D., Hankey, G.J., and Hart, R.G., 2013. Novel Oral Anticoagulants in Secondary Prevention of Stroke. *Best Practice & Research Clinical Haematology* 26 p. 131-139.

- Dubois, E.A. and Cohen, A.F., 2010. Dabigatran Etextilate. ***British Journal of Clinical Pharmacology*** 70 p. 14-15.
- Eapen, R.P., Parikh. J.H., and Patel, N.T., 2009. A Study of Clinical Profile and Risk Factors of Cerebrovascular Stroke. ***Gujarat Meical Journal***, Vol. 64 No. 2 p. 47-53
- Fagan, S., & Hess, D., 2008. Stroke. In J. Dipiro, R. Talbert, G. Yee, G. Matzke, B. Wells, & L. Posey, ***Pharmacotherapy a Pathophysiologic Approach 7th Ed.*** United States: The McGraw Hill Companies, Inc., p. 374.
- Fahimfar, N., Khalili, D., Mohebi, R., Azizi, F., and Hadaegh, F., 2012. Risk Factors for Ischemic Stroke; Results From 9 Years of Follow-up in A Population Based Cohort of Iran. ***BioMed Central Neurology***, p. 1-7.
- Firriolo, F.J. and Hupp, W.S., 2012. Beyond Warfarin: The New Generation of Oral Anticoagulants and Their Implications for the Management of Dental Patients. ***Medical Management and Pharmacology Update***, vol. 113 no. 4, p. 437.
- Fischbach, F.T., Eds. 2004. ***Manual oLaboratory & Diagnostic Tests***. 7<sup>th</sup> Ed. Wisconsin: Lippincott.
- Font, M.A., Krupinski, J., and Arboix, A., 2011. Antithrombotic Medication for Cardioembolic Stroke Prevention. ***Stroke Research and Treatment*** Volume 2011.
- Gama, H., 2008. Drug Utilization Studies. ***Arquivos De Medicina***, vol. 22 p. 69-74.
- Greenberg, D.A., Aminoff, M.J., and Simon, R.P., 2012. ***Clinical Neurology. 8<sup>th</sup> edition***, United States of America: Mc Graw Hill Companies, p. 380.
- Hanley, C.M. and Kowey, P.R., 2015. Are the Novel Anticoagulants Better than Warfarin for Patients with Atrial Fibrillation? ***Journal of Thoracic Disease***, p. 165-171.

- Kelompok Studi Stroke PERDOSSI,. 2011. *Guideline Stroke*. Jakarta.
- Keputusan Menteri Kesehatan Republik Indonesia Nomor 1455/MENKES/SK/X/2010 tentang Formularium Program Jaminan Kesehatan Masyarakat. Menteri Kesehatan Republik Indonesia. Jakarta.
- Keputusan Menteri Kesehatan Republik Indonesia Nomor 89/MENKES/SK/II/2013 tentang Formularium Program Jaminan Kesehatan Masyarakat. Menteri Kesehatan Republik Indonesia. Jakarta.
- Keputusan Menteri Kesehatan Republik Indonesia Nomor 328/MENKES/SK/VIII/2013 tentang Formularium Nasional. Menteri Kesehatan Republik Indonesia. Jakarta.
- Hallevi, Hen, Albright, K.C., Martin-Schild, S., Barreto, A.D., Savitz, S.I., Escobar, M.A., Gonzales, N.R., Noser, E.A., Illoh, K., and Grotta, J.C., 2008. Anticoagulation After Cardioembolic Stroke: To Bridge or Not to Bridge? *NIH Public Access*.
- Hankey, G.J., 2013. Secondary Stroke Prevention. *The Lancet Neurology* Vol. 13 p. 178-194
- Harvey S. Stroke. Diakses dari [http://health.shorehealth.org/patiented/articles/stroke\\_000465.htm](http://health.shorehealth.org/patiented/articles/stroke_000465.htm) , pada 26 Januari 2015 pukul 18.56
- Hata, J. and Kiyohara, Y., 2013. Epidemiology of Stroke and Coronary Artery Disease in Asia. *Circulation Journal*.
- Hinkle, J.L. and Guanci, M.M., 2007. Acute Ischemic Stroke Review. *Journal of Neuroscience Nursing*, p. 287.
- Hirsh, J., Fuster, V., Ansell, J., and Halperin J.L., 2003. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. *AHA/ACC*

**Scientific Statement.** American Heart Association, Inc. and the American College of Cardiology Foundation, p. 4-9.

- Irawati, S. 2014. Apixaban: Antikoagulan Oral Baru-Penghambat Spesifik Faktor Xa. *Medikamen* No. 22.
- Jauch, E.C., Saver, J.L., Adams, H.P., Bruno, A., Connors, J.J., Demaerschalk, B.M., Khatri, P., McMullan, P.W., Qureshi, A.I., Rosenfield, K., Scott, P.A., Summers, D.R., Wang, D.Z., Wintermark, M., and Yonas, H., 2013. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: ***A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.*** American Heart Association Inc.
- Baxter, K. 2008. Stockley's Drug Interactions 8<sup>th</sup> edition. London: Pharmaceutical Press
- Keeling, D., Baglin T., Tait, C., Watson, H., Perry, D., Baglin, C., Kitchen S., and Makris M., 2011. Guidelines on Oral Anticoagulation with Warfarin-Fourth Edition. ***British Journal of Haematology Guideline*** 154, p. 311-324.
- Kementerian Kesehatan Republik Indonesia. Diakses dari <http://www.depkes.go.id/article/print/2014072000001/presiden-resmikan-rs-pusat-otak-nasional.html> , pada 5 Februari 2015 pukul 23.07
- Kernan, W.N., Ovbiagale, B., Black, H.R., Bravata, D.M., Chimowitz, M.I., Ezekowitz, M.D., Fang, M.C., Fisher, M., Furie, K.L., Heck, D.V., Johnston, C., Kasner, S.E., Kittner, S.J., Mitchell, P.H., Rich, M.W., Richardson, D., Schwamm, L.H., and Wilson, J.A., 2014. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: ***A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.*** American Heart Association Inc.

- Kreutz, R., 2011. Pharmacodynamic and Pharmacokinetic basics of Rivaroxaban. *Fundamental Clinical & Pharmacology* 26, p. 27-32
- Kumar, V., Cotran, R.S., and Robbins, S.L. 2012. *Buku Ajar Patologi Robbins* Ed. 7, Vol. 1. Diterjemahkan oleh Prasetyo, A., Asroruddin, M., Pedit, B.U., dan Priliono, T. Jakarta: Penerbit Buku Kedokteran EGC
- Lam, Y.-Y., Ma, T.K.W., and Yan, B.P., 2011. Alternatives to chronic warfarin therapy for the prevention stroke in patients with atrial fibrillation. *International Journal of Cardiology* 150, p. 4-11
- Lane, D.A. and Lip, G.Y.H., 2012. Use of the CHA<sub>2</sub>DS<sub>2</sub>-Vasc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation. *Circulation*, p. 861.
- Lip, G.Y.H., 2010. Implications of the CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED Scores for Thromboprophylaxis in Atrial Fibrillation. *The American Journal of Medicine*, p. 1-4.
- Larsen, T.B., Rasmussen, L.H., Skjoth, F., Due, K.M., Callreus, T., Rosenzweig, M., and Lip, G.Y.H., 2013. Efficacy and Safety of Dabigatran Etxilate and Warfarin in “Real-World” Patients With Atrial Fibrillation. *Journal of The American Colege of Cardiology* vol. 61 no. 22, p. 2270.
- Maas, M.B. and Safdieh, J.E., 2009. Ischemic Stroke : Pathophysiology and Principles of Localization. *The Hospital Physician Neurology Board Review Manual* Volume 13 Part 1 p. 2.
- Majerus, P., and Tollefsen, D. 2006. Blood Coagulation and Anticoagulant, Thrombolytic, and Antiplatelet Drugs. In M. P. Division, *Goodman & Gilman's The Pharmacological Basis of Therapeutics 11th Ed.* USA. The McGraw Hill Corporation, Inc.

- Makris, M., Veen, J.J.V., Tait, C.R., Murnford, A.D., and Laffan, M., 2012. Guideline on the Management of Bleeding in Patients on Antithrombotic Agents. *British Journal Of Haematology Guideline* 160, p. 35-46.
- Mardjono, M. dan Sidharta, P., 2012. *Neurologi Klinis Dasar*. Jakarta: Dian Rakyat, hal. 270-286.
- Melissa, H., Miller, S., Reed, B., and Miller, A., 2012. Management of Rivaroxaban in Adults. *UNC Health Care Guideline*, p. 1-6.
- Mil, F. 2005. Drug-related Problems: A Conerstone for Pharmaceutical Care. *Journal of the Malta College of Pharmacy Practice.*, Hal. 5-8
- Mueller, R.L., 2004. First-Generation Agents: Aspirin, Heparin, and Coumarins. *Best Practice & Research Clinical Haematology*, vol. 17 no. 1 p. 30.
- NIH. What Are The Signs and Symptoms of Atrial Fibrillation. Diakses dari <http://www.nhlbi.nih.gov/health/helath-topics/topics/af/signs> , pada tanggal 26 Januari pukul 00.07.
- Nursalim, A. dan Setiabudi, E., 2012. Efektivitas Antikoagulan Baru Dibandingkan dengan Warfarin dalam Mencegah Stroke pada Pasien Atrial Fibrilasi. *Journal of The Indonesian Medical Association* , Vol. 62 No. 10, p. 407-411.
- Paciaroni, M., Agnelli, G., Micheli, S., and Caso, V., 2007. Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke. *Stroke*, P. 423-430.
- Palm, F., Urbanek, C., Wolf, J., Buggle, F., Kleeman, T., Hennerici, M.G., Inselmann, G., Hagar, M., Safer, A., Becher, H., Grau, A.J., 2012. Etiology, Risk Factors and Sex Differences in Ischemic Stroke in the Ludwigshafen Stroke Study, a Population-Based Stroke Registry. *Cerebrovascular Diseases*, 33 p. 69-75

- Perzborn, E., Roehrig, S., Straub, A., Kubitz, D., Mueck, W., and Laux, V. Rivaroxaban: A New Oral Factor Xa Inhibitor. *Journal of The American Heart Association*, p. 378-379
- Petersen, E. 2012. Preventing Stroke in Patients with Atrial Fibrillation. Retrieved from the University Minnesota Digital Conservancy, <http://purl.umn.edu/129000>
- Pisters, R., Lane, D.A., Nieuwlaet, R., de Vos, C.B., Crijns, H.J.G.M., and Lip, G.Y.H., 2010. A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation: The Euro Heart Survey. *CHEST : Official publication of The American College of Chest Physicians*, p. 1095
- Popescu, R., Dan, G.A., and Buzea, A., 2013. Secondary Prevention in Patients With Atrial Fibrillation and Stroke or Transient Ischemic Attack – an Insight From The Facts Programme. *Romanian Journal of Neurology* Vol. XII, No. 3 p. 131
- Price, S.A., and Wilson, L.M. eds. 2006. *Patofisiologi : Konsep Klinis Proses-Proses Penyakit*. Ed. 6. Diterjemahkan oleh Pendi, B.U., Hartanto, H., Wulansari, P., Susi, N., dan Mahanani, D.A. Jakarta: Penerbit Buku Kedokteran EGC
- Roldan, V., Marin, F., Manzano-Fernandez, S., Gallego, P., Vilchez, J.A., Valdes, M., Vicente, V., and Lip, G.Y.H., 2013. The HAS-BLED Score Has Better Prediction Accuracy for Major Bleeding Than CHA<sub>2</sub>DS<sub>2</sub>-VASc Scores in Anticoagulated Patients With Atrial Fibrillation. *Journal of the American College of Cardiology* Vol. 62 No. 23, p. 2200.
- Roveny, 2015. Antikoagulan untuk Stroke Iskemik Kardioemboli. *Cermin Dunia Kedokteran 228*, vol. 42 no. 5 hal. 348-349.
- Sacco, R.L., Adams, R., Albers, G., Alberts, M.J., Benavente, O., Furie, K., Goldstein L.B., Gorelick, P., Halperin, J., Harbaugh, R., Johnston, C., Katzan, I., Kelly-Hayes, M., Kenton, E.J., Marks, M., Schwann, L.H., Tomsick, T., 2006. Guidelines for Prevention of Stroke in Patients With



Ischemic Stroke or Transient Ischemic Attack. *AHA/ASA Guideline*, p. 590.

- Sacco, R.L., *et.al.* 2013. An Updated Definition of Stroke for the 21<sup>st</sup> Century. *AHA/ASA Expert Consensus Document* p. 2066.
- Sachdeva, P.D. and Patel, B.G., 2010. Drug Utilization Studies-Scope And Future Perspectives. *International Journal on Pharmaceutical and Biological Research* Volume 1, p. 11-17.
- Sardar, P., Chatterjee, S., Wu, W., Lichstein, E., Ghosh, J., Aikat, S., and Mukherjee, D., 2013. New Oral Anticoagulants Are Not Superior to Warfarin in Secondary Prevention of Stroke or Transient Ischemic Attacks, but Lower the Risk of Intracranial Bleeding: Insights from a Meta-Analysis and Indirect Treatment Comparisons. *PLOS ONE*, p. 1-3.
- Shalini, S., Ravichandran, V., Mohanty, B.K., Dhanaraj, S.K., and Saraswathi, R., 2010. Drug Utilization Studies – An Overview. *International Journal of Pharmaceutical Sciences and Nanotechnology* Volume 3 Issue 1, p. 805.
- Silva, G.S., Koroshetz W.J., Gonzalez, R.G., and Schwamm L.H., 2011. Causes of Ischemic Stroke. *Acute Ischemic Stroke*, p. 39.
- Skanes, A.C., Healey, J.S., Cairns, J.A., Dorian, P., Gilis, A.M., McMurtry, M.S., Mitchell, L.B., Verma, A., and Nattel, S., 2012. Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control. *Canadian Journal of Cardiology*, p. 130.
- Spence, D. and Barnett, H.J.M., 2012. *Stroke Prevention, Treatment, and Rehabilitation*. United States: Mc Graw Hill Companies, p. 2.
- Spengos, K. and Vemmos, 2010. Etiology and Outcome of Cardioembolic Stroke in Young Adults in Greece. *Hellenic Journal of Cardiology* 51 p. 127

- Tatro, D.S., 2003. *A to Z Drug Facts*. Facts and Comparison.
- Tatro, D.S., 2009. *Drug Interaction Facts*. California: Facts & Comparison Publishing Group
- Tjay, T.H. dan Rahardja, K., 2008. *OBAT-OBAT PENTING Khasiat, Penggunaan dan Efek-Efek Sampingnya* Edisi 6. Jakarta: PT. Elex Media Komputindo, hal. 612.
- Tran, H., Joseph, J., Young, L., McRae, S., Curnow, J., Nandurkar, H., Wood, P., and McLintock, C., 2014. New Oral Anticoagulants: a Practical guide on Prescription, Laboratory Testing and Peri-procedural/Bleeding Management. *Internal Medicine Journal* 44, p. 1-12.
- Truelsen, T., Begg, S., and Mathers, C., 2006. The Global Burden of Cerebrovascular Disease. *Cerebrovascular Disease*, p. 1
- Truter, I., 2008. A Review of Drug Utilization Studies and Methodologies. *Jordan Journal of Pharmaceutical Sciences*, Volume 1, No. 2 p. 91.
- Tullio, M.R.D. and Homma, S., 2002. Mechanisms of Cardioembolic Stroke. *Current Cardiology Reports* Vol. 4 Issue 2, p. 141-148
- Ueshima, H., Sekikawa, A., Miura, K., Turin TC, Takashima, N., Kita, Y., Watanabe, M., Kadota, A., Okuda, N., Kadowaki, T., Nakamura, Y., and Okamura, T., 2008. Cardiovascular disease and risk factors in Asia: A selected review. *Circulation*.
- U.S. National Institute of Neurological Disorders and Stroke (2009) *Stroke : Challenges, Progress and Promises*. U.S. : NIH Publication p. 2
- Vorvick, L.J., 2011. Developmental process of atherosclerosis. Diakses dari <http://www.nlm.nih.gov/medlineplus/ency/imagepages/18020.htm> , pada 17 Maret 2015 pukul 07.45

- Weitz, J.I. and Gross, P.L., 2012. New Oral Anticoagulants: Which One Should My Patient Use? *Hematology: The New Era In Antithrombotic Therapy*, p. 536-537.
- Wienbergen, H. and Zeymer, U., 2007. Management of acute coronary syndromes with Fondaparinux. *Vasc Health Risk Manag* 3, p. 321-329
- Wilmott, M., Leonardi-Bee, J., and Bath, P.M.W., 2004. High Blood Pressure in Acute Stroke and Subsequent Outcome. *Hypertension*, p. 18-24.
- Winkle, R.A., Mead, R.H., Engel, G., Kong, M.H., and Patrawala, R.A., 2014. Comparison of CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASC Anticoagulation Recommendations: Evaluation in A Cohort of Atrial Fibrillation Ablation Patients. *Europace*, p. 196-198.
- Winkler, S, 2008. Stroke. In M. Chisholm-Burns, B. Wells, T. Schwinghammer, P. Malone, J. Kolesar, J. Rotschafer, et al., *Pharmacotherapy Principles and Practice*. USA: The McGraw-Hill Companies, Inc, p. 162.
- World Health Organization. 2003. Introduction to Drug Utilization Research. Switzerland: World Health Organization.
- Zehnder, J.L. eds. 2012. *Farmakologi Dasar & Klinik*. Ed. 10. Diterjemahkan oleh Nugroho, A.W., Rendy, L., dan Dwijayanthi, L. Jakarta: Penerbit Buku Kedokteran EGC, hal. 559.
- Zhang, J., Wang, Y., Wang, G., Sun, H., Sun, T., Shi, J., Xiao, H. Zhang, J., 2011. Clinical Factors in Patients With Ischemic Versus Hemorrhagic Stroke in East China. *World Journal of Emergency Medicine*, vol. 2 no. 1, p. 18-23.
- Zhang, Z., Yan, J., and Shi, H., 2013. Hyperglycemia as a Risk Factor of Ischemic Stroke. *Journal of Drug and Metabolism Toxicology*, vol. 4 issue 4, p. 1-5